



Fax completed form to: (855) 840-1678

If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Aralast NP, Glassia, Prolastin C, Zemaira

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: ICD10: ☐ Aralast NP 500mg vial ☐ Aralast NP 1000mg vial ☐ Glassia 1000mg vial ☐ Prolastin C 1000mg vial ☐ Zemaira 1000mg vial ☐ Zemaira 4000mg vial ☐ Zemaira 5000mg vial Dose: Frequency of therapy: Duration of therapy: What is your patient's current weight? lb/kg (circle one) Is this a new start or continuation of therapy?*** ☐ new start of therapy ☐ continued therapy, start date: ***If your patient has already begun treatment with drug samples, please choose "new start of therapy".					
Where will this medication be obtained? ☐ Accredo Specialty Pharmacy** ☐ Hospital Outpatient ☐ Retail pharmacy ☐ Other (please specify): ☐ Home Health / Home Infusion vendor ☐ Physician's office stock (billing on a medical claim form) **Cigna's nationally preferred specialty pharmacy **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code):					
Where will this drug be administered? ☐ Patient's Home ☐ Hospital Outpatient ☐ Physician's Office ☐ Other (please specify): NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting. Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No					

What is your patient's diagnosis?

- ☐ Alpha1-Antitrypsin Deficiency-Associated Panniculitis
☐ Alpha1-antitrypsin deficiency with emphysema (or chronic obstructive pulmonary disease [COPD])
☐ Alpha1-Antitrypsin Deficiency without Lung Disease, even if Deficiency-Induced Hepatic Disease is Present
☐ Bronchiectasis (without alpha1-antitrypsin deficiency)
☐ Chronic Obstructive Pulmonary Disease (COPD) without Alpha1-Antitrypsin Deficiency
☐ All other indications

(if other indications and requesting Aralast NP or Zemaira) What is the diagnosis related to use?

Clinical Information**(if Aralast, Zemaira are being requested):**

Is documentation being provided that the patient has tried and cannot take BOTH of the following (1 and 2): 1. Glassia; and 2. Prolastin-C (powder or liquid)? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

FOR ALL REQUESTS:

Is documentation being provided that the patient has a baseline (pretreatment) alpha1-antitrypsin serum concentration of less than 11 mcM (11 mmol/L) [less than 80 mg/dL if measured by radial immunodiffusion or less than 57 mg/dL if measured by nephelometry]? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

Is documentation being provided that genotyping or phenotyping demonstrates one of the following types: ZZ, (null)(null), Z(null), SZ or other rare disease-causing alleles associated with serum alpha1-antitrypsin (AAT) level less than 11 mmol/L? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if Alpha1-Antitrypsin Deficiency with Emphysema [or Chronic Obstructive Pulmonary Disease]) At baseline (prior to initiation of an alpha1-proteinase inhibitor), is documentation being provided of a forced expiratory volume in 1 second (FEV1) less than 65% of predicted? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if no) At baseline (prior to initiation of an alpha1-proteinase inhibitor), is documentation provided of an accelerated decline in lung function (accelerated decline in lung function includes FEV1 decline greater than 100 mL/year or a decline in diffusing capacity of the lungs for carbon monoxide [DLCO] greater than 15% per year)? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if no) At baseline (prior to initiation of an alpha1-proteinase inhibitor), is documentation provided that supplemental oxygen required at rest or with exertion? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if Alpha1-Antitrypsin Deficiency with Emphysema [or Chronic Obstructive Pulmonary Disease]) According to the prescriber, is the patient currently a NON-SMOKER? ☐ Yes ☐ No

(if Alpha1-Antitrypsin Deficiency with Emphysema [or Chronic Obstructive Pulmonary Disease]) Is this medication prescribed by or in consultation with a pulmonologist? ☐ Yes ☐ No

(if panniculitis) Is documentation being provided that the diagnosis of panniculitis confirmed by skin biopsy? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if panniculitis) Is documentation being provided that the patient has moderate to severe panniculitis? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if no) Is documentation being provided that the patient has mild panniculitis? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if yes) Has the patient tried dapsone? ☐ Yes ☐ No

(if yes) Is documentation being provided that the patient experienced inadequate efficacy or significant intolerance with dapsone? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if no) Does the patient have a contraindication to dapsone according to the prescriber? ☐ Yes ☐ No

(if panniculitis) Is this medication prescribed by or in consultation with a pulmonologist or dermatologist? ☐ Yes ☐ No

Additional pertinent information:

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v091525

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005